Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Unicycive Therapeutics, Inc. (UNCY : NSDQ)

• Company Description    Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $5.25 Daily Weekly Monthly 20 Day Moving Average: 1,158,871 shares Shares Outstanding: 12.64 (millions) Market Capitalization: $66.36 (millions) Beta: 1.89 52 Week High: $11.00 52 Week Low: $2.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.70% -20.78% 12 Week -12.54% -26.44% Year To Date -33.90% -38.09%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4300 EL CAMINO REAL SUITE 210 - LOS ALTOS,CA 94022 USA ph: 650-351-4495 fax: - ir@unicycive.com http://www.unicycive.com

• General Corporate Information    Officers Shalabh Gupta - Chief Executive Officer; President and Chairman John Townsend - Chief Financial Officer Sandeep Laumas - Director Saraswati Kenkare-Mitra - Director Gaurav Aggarwal - Director Peer Information Unicycive Therapeutics, Inc. (GSAC) Unicycive Therapeutics, Inc. (CASI) Unicycive Therapeutics, Inc. (ALCD.) Unicycive Therapeutics, Inc. (OMNN) Unicycive Therapeutics, Inc. (CGPI.) Unicycive Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 90466Y202 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 12.64 Most Recent Split Date: 6.00 (0.10:1) Beta: 1.89 Market Capitalization: $66.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.73 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.52 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 5.58 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 81.48% vs. Previous Quarter: 80.77% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -277.30 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -61.53 12/31/24 - -59.57 Current Ratio 06/30/25 - - 03/31/25 - 1.64 12/31/24 - 1.28 Quick Ratio 06/30/25 - - 03/31/25 - 1.64 12/31/24 - 1.28 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.94 12/31/24 - 0.72 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©